Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
复制标题
患者对早期乳腺癌机会窗口临床试验的看法。
DOI：
10.1007/s10549-022-06611-6
复制
发表时间：
2022-07
影响因子：
3.8
通讯作者：
Caswell-Jin, Jennifer L.
中科院分区：
文献类型：
--
作者：
Parikh, Divya A.;Kody, Lisa;Brain, Susie;Heditsian, Diane;Lee, Vivian;Curtis, Christina;Karin, Mardi R.;Wapnir, Irene L.;Patel, Manali, I;Sledge, George W., Jr.;Caswell-Jin, Jennifer L.
机会之窗试验（WOT）在肿瘤学研究中越来越常见。在WOT中，参与者在诊断和抗癌治疗之间接受药物，通常是为了研究药物对癌症生物学的影响。这项定性研究旨在了解患者对WOT的看法。我们招募了在一个单一的学术医疗中心等待确定性治疗的诊断为早期乳腺癌的成年人参加半结构化访谈。主题和内容进行分析，以确定的态度和因素，将影响有关WOT参与的决定。我们采访了25名被诊断为早期乳腺癌的妇女。对参与试验最常见的积极态度是希望为研究做出贡献并希望获得个人利益，而最常见的担忧是副作用的可能性以及它们如何影响计划治疗的适应性。参与者表示，家庭将是决策中的一个重要规范性因素，在COVID-19大流行期间，他们认为在诊所就诊期间没有家庭成员是入组的障碍。可能阻碍参与的因素包括标准治疗的延迟和额外访视或程序的要求。最终，大多数受访者表示，如果提供，他们将参加WOT（N = 17/25）。在这项定性研究中，受访者权衡利他主义和假设的个人利益的可能性，从WOT的副作用。在2019冠状病毒病期间具有挑战性的审判讨论期间，家人亲自出席对许多人来说很重要。我们的研究结果可能会在未来的机会窗口工作中为试验设计和沟通方法提供信息。在线版本包含补充材料，可通过10.1007/s10549-022-06611-6获得。
Window of opportunity trials (WOT) are increasingly common in oncology research. In WOT participants receive a drug between diagnosis and anti-cancer treatment, usually for the purpose of investigating that drugs effect on cancer biology. This qualitative study aimed to understand patient perspectives on WOT. We recruited adults diagnosed with early-stage breast cancer awaiting definitive therapy at a single-academic medical center to participate in semi-structured interviews. Thematic and content analyses were performed to identify attitudes and factors that would influence decisions about WOT participation. We interviewed 25 women diagnosed with early-stage breast cancer. The most common positive attitudes toward trial participation were a desire to contribute to research and a hope for personal benefit, while the most common concerns were the potential for side effects and how they might impact fitness for planned treatment. Participants indicated family would be an important normative factor in decision-making and, during the COVID-19 pandemic, deemed the absence of family members during clinic visits a barrier to enrollment. Factors that could hinder participation included delay in standard treatment and the requirement for additional visits or procedures. Ultimately, most interviewees stated they would participate in a WOT if offered (N = 17/25). In this qualitative study, interviewees weighed altruism and hypothetical personal benefit against the possibility of side effect from a WOT. In-person family presence during trial discussion, challenging during COVID-19, was important for many. Our results may inform trial design and communication approaches in future window of opportunity efforts. The online version contains supplementary material available at 10.1007/s10549-022-06611-6.
登录
查看更多内容
DOI：
10.1016/0749-5978(91)90020-t
发表时间：
1991-12-01
影响因子：
4.6
作者：
AJZEN, I
通讯作者：
AJZEN, I
影响因子：
1.5
作者：
Arnaout, Angel;Robertson, Susan;Clemons, Mark
通讯作者：
Clemons, Mark
影响因子：
45.3
作者：
Meropol, NJ;Weinfurt, KP;Schulman, KA
通讯作者：
Schulman, KA
DOI：
10.1093/jnci/95.11.779
发表时间：
2003-06-04
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Decensi, A;Robertson, C;Veronesi, U
通讯作者：
Veronesi, U
DOI：
10.1001/jamahealthforum.2020.0807
发表时间：
2020-07-01
期刊：
JAMA health forum
影响因子：
--
作者：
Frampton, Susan;Agrawal, Shantanu;Guastello, Sara
通讯作者：
Guastello, Sara